

Supplementary Table 3. Treatment responses of HCC among patients with Vp3-Vp4 PVTT before and after IPTW

Parameter	Before IPTW			After IPTW		
	Atezolizumab plus bevacizumab (n=20)	Lenvatinib (n=20)	P-value	Atezolizumab plus bevacizumab (n=20)	Lenvatinib (n=20)	P-value
Objective response			1			0.71
Complete response	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
Partial response	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
Stable disease	4 (20.0)	4 (20.0)		4 (20.0)	4 (19.9)	
Progressive disease	14 (70.0)	15 (75.0)		14 (70.0)	15 (76.5)	
Not evaluable	2 (10.0)	1 (5.0)		2 (10.0)	1 (3.6)	
Objective response rate	0 (0.0)	0 (0.0)	1	0 (0.0)	0 (0.0)	1
Disease control rate	4 (20.0)	4 (20.0)	1	4 (20.0)	4 (19.9)	0.99

Values are presented as number (%).

HCC, hepatocellular carcinoma; PVTT, portal vein tumor thrombosis; IPTW, inverse probability of treatment weighting.